ArticleJournal of medical virology2026
Impact of Epstein-Barr Virus Donor Serostatus on Post-Transplant Mortality and Post-Transplant Lymphoproliferative Disorder in Epstein-Barr Virus Seropositive Thoracic Organ Transplant Recipients: Data from the Organ Procurement and Transplantation Network.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Donor Epstein-Barr virus (EBV)-seropositive (D + ) serostatus is a risk factor for post-transplant lymphoproliferative disorder (PTLD) in EBV-seronegative recipients. The impact of donor EBV serostatus on mortality and PTLD in EBV-seropositive (R + ) thoracic organ transplant recipients is unknown. We analyzed 49 458 EBV R+ thoracic transplant recipients from the Organ Procurement and Transplantation Network (2004-2021). The primary exposure was EBV D+ serostatus; outcomes were death and PTLD. Associations were assessed using multivariable Cox and logistic regression models. EBV D+ serostatus was not associated with mortality but significantly reduced the hazard of PTLD in lung and heart-lung (L/HLT) recipients (adjusted hazard ratio, 0.59; 95% CI: 0.42-0.83). No association was observed in heart transplants. Notably, 48.7% of PTLD cases in EBV R + L/HLT occurred early after transplant when the donor was EBV-seronegative (D-). In an exploratory subgroup analysis of PTLD cases, EBV D+ serostatus was associated with lower odds of early vs late PTLD (adjusted odds ratio [aOR]: 0.40; 95% CI: 0.22-0.73). Conversely, L/HLT had twice the odds of early PTLD (aOR: 2.62; 95% CI: 1.68 - 4.08). EBV D-/R + L/HLT recipients carry a substantially higher risk of PTLD than EBV D + /R+ recipients, driven predominantly by early-onset disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.